Skip to main content
For Healthcare Professionals

TRAJENTA®

Dosing and administration

The recommended dose of TRAJENTA® is 5 mg once daily.1

  • TRAJENTA® can be used as an adjunct to diet and exercise as monotherapy or in combination with metformin, sulfonylurea, insulin or PPARγ agonists (such as thiazolidinediones) to improve glycemic control.

  • TRAJENTA® can be taken with or without food.

  • When TRAJENTA® is used in combination with an insulin secretagogue (eg, sulfonylurea) or insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia.

 

0% inappropriate dose risk in patients with renal failure.2

  • Dose adjustment is not required in patients with renal impairment or with hepatic impairment.

Footnote:

  • PPARγ, Peroxisome proliferator-activated receptor γ.

References:

  1. TRAJENTA® approved package insert. Updated in May 2020. 

  2.  Abigail Tebboth et al, Clinical Therapeutics, 38, 8, August 2016, 1825-1832.

Related News

Reporting adverse events

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.